MarketsLupin Limited LUPIN
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated in the browser from validated historical candles. This is descriptive research, not a buy or sell recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 38,364.83 | 29,204.88 | 23,997.18 |
| Accumulated Depreciation Total | -5,534.62 | -4,956.84 | -4,580.63 |
| Cash Equivalents | 4,167.73 | Not available | Not available |
| Other Liabilities Total | 843.19 | 692.23 | 721.08 |
| Accrued Expenses | 759.05 | 512.38 | 419.25 |
| Long Term Debt | 1,643.39 | 1,766.23 | 0 |
| Common Stock Total | 91.44 | 91.32 | 91.14 |
| Other Equity Total | 202.3 | -239.61 | -163.59 |
| Other Current Assets Total | 1,386.64 | 1,235.42 | 37.24 |
| Prepaid Expenses | 114.62 | 104.29 | 99.89 |
| Total Assets | 38,364.83 | 29,204.88 | 23,997.18 |
| Current Portof LT Debt/Capital Leases | 211.11 | 106.85 | 96.58 |
| Additional Paid-In Capital | 1,359.56 | 1,287.59 | 1,179.44 |
| Total Equity | 22,448.27 | 17,203.5 | 14,290.29 |
| Long Term Investments | 92.54 | 97.9 | 227.7 |
| Retained Earnings(Accumulated Deficit) | 20,730.77 | 15,980.22 | 13,068.93 |
| Total Common Shares Outstanding | 45.72 | 45.66 | 45.57 |
| Property/Plant/Equipment Total-Gross | 11,678.88 | 10,460.47 | 10,074.85 |
| Tangible Book Valueper Share Common Eq | 362.71 | 273.15 | 222.39 |
| Goodwill Net | 2,658.53 | 2,232.61 | 2,325.04 |
| Total Liabilities | 15,916.56 | 12,001.38 | 9,706.89 |
| Total Debt | 6,616.18 | 5,447.77 | 2,921.77 |
| Short Term Investments | 3,780.25 | 1,897.97 | 1,467.41 |
| Cashand Short Term Investments | 7,947.98 | 3,020.07 | 2,178.54 |
| Total Receivables Net | 8,112.8 | 6,721.78 | 5,932.06 |
| Notes Payable/Short Term Debt | 4,266.81 | 3,310.42 | 2,669.91 |
| Deferred Income Tax | 218.77 | 226.41 | 245.87 |
| Accounts Receivable-Trade Net | 6,604.06 | 5,497.1 | 4,692.05 |
| Property/Plant/Equipment Total-Net | 6,144.26 | 5,503.63 | 5,494.22 |
| Minority Interest | 65.1 | 90.85 | 83.16 |
| Total Current Liabilities | 12,651.24 | 8,961.39 | 8,501.5 |
| Total Inventory | 6,465.34 | 5,717.02 | 5,199.92 |
| ESOP Debt Guarantee | 64.2 | 83.98 | 114.37 |
| Accounts Payable | 4,173.13 | 2,958.16 | 2,958.11 |
| Other Currentliabilities Total | 3,241.14 | 2,073.58 | 2,357.65 |
| Total Long Term Debt | 2,138.26 | 2,030.5 | 155.28 |
| Intangibles Net | 3,207.2 | 2,499.75 | 1,831.57 |
| Other Long Term Assets Total | 2,020.71 | 1,847.28 | 399.21 |
| Note Receivable-Long Term | 214.21 | 225.13 | 271.79 |
| Total Current Assets | 24,027.38 | 16,798.58 | 13,447.65 |
| Capital Lease Obligations | 494.87 | 264.27 | 155.28 |
| Cash | Not available | 1,122.1 | 711.13 |
Valuation and ratios
Valuation
PEG Ratio0.15
Price to Sale Ratio0.40
Growth
Debt 5Yr CAGR %5.22
Margins
Operating Margin 12m22.27
Operating Margin 5y Avg12.28
Net Profit Margin 12m19.16
Net Profit Margin 5y9.19
Yield
Dividend Yield %0.72
Source-qualified signals
Risk metrics
Overall RiskModerate risk
Board Risk20.83
Recommendations
RatingHold
Target High2,530
Target Low1,838.65
Target Mean2.67
Target Median8.33
Analyst count, source and as-of date are not provided; target values should be treated as unverified.Peer comparison
Only peers present in the company profile payload are displayed.
| Symbol | Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|---|
| — | Sun Pharmaceutical Industries | INR 1,937.3 | 4.65 L | 38.4 | — |
| — | Divi's Laboratories | INR 7,378 | 1.96 L | 73.32 | — |
| — | Torrent Pharmaceuticals | INR 4,981 | 1.69 L | 72.73 | — |
| — | Cipla | INR 1,405.6 | 1.14 L | 27.57 | — |
| — | Zydus Lifesciences | INR 1,118.85 | 1.12 L | 21.19 | — |
Ownership
- Promoter
- 46.85%
- FII
- 22.42%
- MF
- 14.84%
- Other
- 15.89%
Events
- annual General MeetingAGM
- dividendRs.18.0000 per share(900%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsTo consider other business matters.
- annual General MeetingPOM
- annual General MeetingAGM
- board MeetingsTo consider other business matters.
- dividendRs.12.0000 per share (600%) Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsTo consider other business matters.
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.8.0000 per share(400%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Pharma stocks close lower; Lupin down over 4% after Trump announces steep tariffs on generics ET Manufacturing
Lupin Transfers Cancer Drug Assets to Kaveri Therapeutics Pharmacy Business
US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline BusinessLine
Lupin, Aurobindo, Sun Pharma fall up to 4%: Why are pharma stocks falling today? India Today
Gland Pharma, Lupin, Dr Reddy's: All Nifty Pharma Stocks In Red After Trump's Drug Tariff Plan NDTV Profit
Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sen News18
Business information
Lupin Limited is a pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. It has presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, GastroIntestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its ophthalmology portfolio includes over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals across European markets. Its diabetes brands include GIBTULIO, AJADUO, GIBTULIO MET, ONDERO, ONDERO MET, and Huminsulin.
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- Website
- Not available
- Address
- Not available
- NSE Code
- LUPIN
- BSE Code
- 500257
AI analysis
This repository contains no authenticated model-inference API, model version, confidence distribution or forecast timestamp. The Android listing is available; verify report availability, entitlement and pricing inside the app.
Open Google PlayStock FAQ
What is the symbol and ISIN of Lupin?
Lupin has the symbol LUPIN and ISIN - INE326A01037.
What is the current price of Lupin?
Lupin is currently trading at INR 2,424.00.
What are the year high and year low of Lupin?
Lupin has a year high of INR 2,530.00 and a year low of INR 1,838.65.
What is the market capitalization of Lupin?
Lupin has a market capitalization of INR 1.11 lakh crore.
What is the P/E ratio of Lupin?
Lupin has a P/E ratio of 18.66.
What is the dividend yield of Lupin?
Lupin has a dividend yield of 0.72%.
How is the financial performance of Lupin based on revenue, net income, and EPS?
Lupin has revenue of INR 2,79,580.30 crore, net income of INR 53,328.40 crore, and EPS of INR 135.10.
What is the book value of Lupin?
Lupin has a book value of INR 362.71.
What is the debt-to-equity ratio of Lupin?
Lupin has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Lupin?
Lupin has a price-to-book ratio of 6.68 and a price-to-sales ratio of 0.40.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.
